




BioSensus is pioneering the use of miniaturized acoustic sensing technology licensed from Drexel University to enable health care workers and patients to conduct diagnostic and therapeutic monitoring at the bedside and at home (self-testing), using a small and inexpensive hand-held device. In its first application, the company's revolutionary NanoAcoustic Blood Analyzer (NABA) will measure blood coagulation properties, clotting times and platelet function from a single finger stick similar to that used by diabetics for monitoring blood glucose. Each year millions of patients in the U.S. who are using anti-coagulant and anti-thrombotic drugs to prevent formation of blood clots, heart attacks and strokes require regular testing to ensure they are receiving neither too much nor too little medication: too much drug raises the risk of hemorrhage (bleeding), while too little places patients at risk of forming clots (thrombosis). Until now, rapid in-hospital and in-home testing was not feasible — to monitor patients' hemostatic, or blood clotting status, blood samples had to be collected by trained technicians and sent for analysis to central labs. The BioSensus innovative NanoAcoustic technology is also potentially usable in a variety of other monitoring applications including personal health care, clinical monitoring of molecular and cellular factors, and environmental and anti-bioterrorism testing. BioSensus is using its BioAdvance funding to develop the first commercial prototype of NABA.

Disposable NABA BioChip Cross-section



## Management

**Ryszard M. Lec, Ph.D., Co-founder and Chief Scientific Officer**, is Professor at the School of Biomedical Engineering, Science and Health Systems, Drexel University, focusing on applying acoustic, ultrasonic, microwave and optical technologies to sensors for biomedical, chemical, and environmental uses. Dr. Lec has received over 30 research grants and has published over 60 papers. He holds a number of patents in the area of micro-sensors and co-developed several sensor products with various companies. Dr. Lec received his M.S.E.E and Ph.D. degrees from the University of Warsaw.

**J. Yasha Kresh Ph.D., Co-founder and Chief BioMedical Officer**, is Professor of Cardiovascular Medicine and Surgery and Research Director of CT-Surgery and Cardiovascular Biophysics at the Drexel University College of Medicine. He is an internationally recognized cardiovascular researcher, credited for advancing molecular/cellular therapies and enabling technologies (artificial hearts, surgical robotics, cardiac and hemostatic monitoring) for the treatment of cardiovascular disorders, and inventor and patent holder of rate-responsive cardiac pacemakers. Dr. Kresh received a B.S.E.E from the New Jersey Institute of Technology and M.S.Bm.E. and Ph.D. degrees from Rutgers University.

**David M. Wootton, Ph.D., Co-founder and Senior Scientist**, is Assistant Professor of Mechanical Engineering and Mechanics at Drexel University. Dr. Wootton's research expertise includes the dynamics and kinetics of blood clotting, thrombosis, and thrombolytic therapy. He also is a co-inventor of the intellectual property that launched Salumedica, a successful medical biomaterial startup company. Dr. Wootton received a B.S. from Cornell, a M.S. from Massachusetts Institute of Technology and a Ph.D. from Georgia Institute of Technology.

**For more information, contact:** Dr. J. Yasha Kresh, BioSensus LLC, DU-College of Medicine, 245 North 15th Street, MS# 111, Philadelphia, PA 19102-1192, e-mail: j.yasha.kresh@drexel.edu, p: 215.762.1703; f: 215.762.5021